Download PDF
CC BY 4.0 · World J Nucl Med 2023; 22(04): 300-305
DOI: 10.1055/s-0043-1777692
Case Report

Clinical Benefit of Radioiodine Administration in a Rare Case of Iodine Avid Thyroid Carcinoma with No Secretion of Thyroglobulin

A. Mouaden 
1   Nuclear Medicine Department, Ibn Sina Teaching Hospital, FMPR, Mohammed V University, Rabat, Morocco
,
H. Guerrouj
1   Nuclear Medicine Department, Ibn Sina Teaching Hospital, FMPR, Mohammed V University, Rabat, Morocco
,
I. Ghfir
1   Nuclear Medicine Department, Ibn Sina Teaching Hospital, FMPR, Mohammed V University, Rabat, Morocco
,
Ben Rais Aouad N
1   Nuclear Medicine Department, Ibn Sina Teaching Hospital, FMPR, Mohammed V University, Rabat, Morocco
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Differentiated thyroid cancer (DTC) is the most common endocrine cancer and its outcome is usually favorable. Its basic treatment is well codified, but its monitoring is much less. The value of thyroglobulin (Tg) is one of the main elements for monitoring DTC, while the use of iodine scintigraphy is becoming less recommended. In this case report, we discuss a clinical situation where a patient presented differentiated thyroid metastatic lesions confirmed by biopsy, uptaking radioactive iodine, with undetectable levels of Tg (in the absence of autoantibodies). We discuss the various hypotheses explaining this clinical situation, the potential advantages of performing periodic iodine scintigraphy in some intermediate and high-risk patients and report the documented clinical benefit of radioiodine therapy.

Keywords

differentiated thyroid cancer - thyroglobulin - radioiodine treatment

Authors' Contributions

Authors contributed equally in the analysis of the patients clinical data. The text writing was mainly done by the corresponding author.




Publication History

Article published online:
26 December 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338 (05) 297-306
    CrossrefPubMedGoogle Scholar
  • 2 Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 2000; 10 (09) 767-778
    CrossrefPubMedGoogle Scholar
  • 3 Pellegriti G, Scollo C, Regalbuto C. et al. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. Clin Endocrinol (Oxf) 2003; 58 (05) 556-561
    CrossrefPubMedGoogle Scholar
  • 4 Gozde Ozkan Z, Adalet I, Turkmen C. et al. Evaluation of discordance in differentiated thyroid cancer patients with negative radioiodine scans and positive thyroglobulin values at the ablation outcome control. Balkan Med J 2012; 29: 43-48
    CrossrefGoogle Scholar
  • 5 Oh JR, Ahn BC. False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer. Am J Nucl Med Mol Imaging 2012; 2 (03) 362-385
    PubMedGoogle Scholar
  • 6 Ma C, Kuang A, Xie J, Ma T. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med 2005; 46 (09) 1473-1480
    PubMedGoogle Scholar
  • 7 Grant S, Luttrell B, Reeve T. et al. Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinoma. Cancer 1984; 54 (08) 1625-1628
    CrossrefPubMedGoogle Scholar
  • 8 Müller-Gärtner HW, Schneider C. Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer 1988; 61 (05) 976-981
    CrossrefPubMedGoogle Scholar
  • 9 Brendel AJ, Lambert B, Guyot M. et al. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. Eur J Nucl Med 1990; 16 (01) 35-38
    CrossrefPubMedGoogle Scholar
  • 10 Park EK, Chung JK, Lim IH. et al. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging 2009; 36 (02) 172-179
    CrossrefPubMedGoogle Scholar
  • 11 d'Herbomez M, Lion G, Béron A, Wémeau JL, DoCao C. Advances in thyroglobulin assays and their impact on the management of differentiated thyroid cancers. Ann Biol Clin (Paris) 2016; 74 (01) 21-27
    PubMedGoogle Scholar
  • 12 Mariotti S, Cupini C, Giani C. et al. Evaluation of a solid-phase immunoradiometric assay (IRMA) for serum thyroglobulin: effect of anti-thyroglobulin autoantibody. Clin Chim Acta 1982; 123 (03) 347-355
    CrossrefPubMedGoogle Scholar
  • 13 Rubello D, Girelli ME, Casara D, Piccolo M, Perin A, Busnardo B. Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 1990; 13 (09) 737-742
    CrossrefPubMedGoogle Scholar
  • 14 Spencer CA. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 2004; 89 (08) 3702-3704
    CrossrefPubMedGoogle Scholar
  • 15 Morgenthaler NG, Froehlich J, Rendl J. et al. Technical evaluation of a new immunoradiometric and a new immunoluminometric assay for thyroglobulin. Clin Chem 2002; 48 (07) 1077-1083
    CrossrefPubMedGoogle Scholar
  • 16 Bätge B, Dralle H, Padberg B, von Herbay B, Schröder S. Histology and immunocytochemistry of differentiated thyroid carcinomas do not predict radioiodine uptake: a clinicomorphological study of 62 recurrent or metastatic tumours. Virchows Arch A Pathol Anat Histopathol 1992; 421 (06) 521-526
    CrossrefPubMedGoogle Scholar
  • 17 Zanotti-Fregonara P, Grassetto G, Hindié E, Rubello D. A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009; 36 (02) 169-171
    CrossrefPubMedGoogle Scholar
  • 18 Haugen BR, Alexander EK, Bible KC. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26 (01) 1-133
    CrossrefPubMedGoogle Scholar
  • 19 Zerdoud S, Giraudet AL, Leboulleux S. et al. Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. Ann Endocrinol (Paris) 2017; 78 (03) 162-175
    CrossrefPubMedGoogle Scholar